Print

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

https://www.facingourrisk.org/research-clinical-trials/study/179/targeted-therapy-rp-3500-alone-or-in-combination-with-talazoparib-or-gemcitabine-in-advanced-solid-tumors-with-dna-damage-repair-mutations-tresr-study

Clinicaltrials.gov identifier:
NCT04497116 (https://clinicaltrials.gov/show/NCT04497116)


Advanced solid tumors

Study Contact Information:

Study coordinator:
Billy Hoadley [email protected]

About the Study

This study is looking at how well a drug called called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.

This study is no longer enrolling people.

This Study is Open To:

This study is no longer enrolling people.

This Study is Not Open To:

This study is no longer enrolling people.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.